India, Oct. 28 -- 60 Degrees Pharmaceuticals, Inc. (SXTP) a pharmaceutical company focused on developing new medicines for vector-borne diseases, announced a sponsored research agreement with The University of Southern Mississippi (USM) to evaluate the therapeutic potential of castanospermine, a naturally occurring iminosugar derived from the Australian chestnut (Castanospermum australe), in nonclinical models of alpha-gal syndrome (AGS).
Alpha-gal syndrome (AGS) is a tick-borne allergy that can cause severe reactions to mammalian meat and other alpha-gal-containing products. There are currently no FDA-approved treatments, with management focused on avoiding triggers.
The partnership leverages The University of Southern Mississippi's (USM...